Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH
Open Access
- 28 March 2017
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (7), 2301-2309
- https://doi.org/10.1210/jc.2017-00166
Abstract
Introduction and Aim:Cumulative time-dependent excess mortality in hyperthyroid patients has been suggested. However, the effect of antithyroid treatment on mortality, especially in subclinical hyperthyroidism, remains unclarified. We investigated the association between hyperthyroidism and mortality in both treated and untreated hyperthyroid individuals.Patients and Methods:Register-based cohort study of 235,547 individuals who had at least one serum thyroid-stimulating hormone (TSH) measurement in the period 1995 to 2011 (7.3 years median follow-up). Hyperthyroidism was defined as at least two measurements of low serum TSH. Mortality rates for treated and untreated hyperthyroid subjects compared with euthyroid controls were calculated using multivariate Cox regression analyses, controlling for age, sex, and comorbidities. Cumulative periods of decreased serum TSH were analyzed as a time-dependent covariate.Results:Hazard ratio (HR) for mortality was increased in untreated [1.23; 95% confidence interval (CI), 1.12 to 1.37; P < 0.001], but not in treated, hyperthyroid patients. When including cumulative periods of TSH in the Cox regression analyses, HR for mortality per every 6 months of decreased TSH was 1.11 (95% CI, 1.09 to 1.13; P < 0.0001) in untreated hyperthyroid patients (n = 1137) and 1.13 (95% CI, 1.11 to 1.15; P < 0.0001) in treated patients (n = 1656). This corresponds to a 184% and 239% increase in mortality after 5 years of decreased TSH in untreated and treated hyperthyroidism, respectively.Conclusions:Mortality is increased in hyperthyroidism. Cumulative periods of decreased TSH increased mortality in both treated and untreated hyperthyroidism, implying that excess mortality may not be driven by lack of therapy, but rather inability to keep patients euthyroid. Meticulous follow-up during treatment to maintain biochemical euthyroidism may be warranted.Keywords
This publication has 34 references indexed in Scilit:
- Graves’ DiseaseNew England Journal of Medicine, 2016
- HyperthyroidismThe Lancet, 2016
- Duration of Thyroid Dysfunction Correlates with All-Cause Mortality. The OPENTHYRO Register CohortPLOS ONE, 2014
- Subclinical and Overt Thyroid Dysfunction and Risk of All-Cause Mortality and Cardiovascular Events: A Large Population StudyJournal of Clinical Endocrinology & Metabolism, 2014
- Low Serum Thyrotropin Level and Duration of Suppression as a Predictor of Major Osteoporotic Fractures—The OPENTHYRO Register CohortJournal of Bone and Mineral Research, 2014
- Morbidity before and after the Diagnosis of Hyperthyroidism: A Nationwide Register-Based StudyPLOS ONE, 2013
- Excess Mortality in Hyperthyroidism: The Influence of Preexisting Comorbidity and Genetic Confounding: A Danish Nationwide Register-Based Cohort Study of Twins and SingletonsJournal of Clinical Endocrinology & Metabolism, 2012
- Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studiesActa Endocrinologica, 2012
- A critical review and meta-analysis of the association between overt hyperthyroidism and mortalityActa Endocrinologica, 2011
- Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based studyActa Endocrinologica, 2011